Protagonist Therapeutics (NASDAQ:PTGX) just reported results for the second quarter of 2024.
- Protagonist Therapeutics reported earnings per share of -50 cents. This was above the analyst estimate for EPS of -60 cents.
- The company reported revenue of $4.17 million.
- This was 47.91% worse than the analyst estimate for revenue of $8.00 million.